
### PATENT COOPERATION TREATY

## **PCT**



# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	1					
04P400146	FOR FURTHER ACTION See Form PCT/IPEA/416					
International application No.	International filing of	late (day/month/year)	Priority date (day/month/year)			
PCT/CN2004/000803		2004(13.07.04)	16.Jan.2004(16.01.04)			
International Patent Classification (IPC) or	national classification	and IPC				
IPC <sup>7</sup> :A61K9/127,38/21,A61P31/12						
Applicant						
SHENZHEN NEPTUNUS IN	TERLONG BIO-TEC	HNIQUE HOLDINGS CO.	LTD. etal.			
	nary examination rep	ort established by this Into-	national Preliminary Examining Authority			
2. This REPORT consists of a total of	2. This REPORT consists of a total of 3 sheets, including this cover sheet.					
3. This report is also accompanied by AN						
<ul> <li>a.          (sent to the applicant and to the International Bureau) a total of 1 sheets, as follows:         sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</li> </ul>						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
Box No. I Basis of the rep	ort					
☐ Box No. II Priority						
		gard to novelty, inventive ste	p and industrial applicability			
☐ Box No. IV Lack of unity of						
	ent under Article 35(2)	with regard to novelty, inve	ntive step or industrial applicability;			
	anations supporting s	ich statement				
Box No. VI Certain documen						
	the international app					
☐ Box No. VIII Certain observat	ions on the internation	nal application				
Date of submission of the demand		Date of completion of this report				
06.Apr.2005(06.04.2002)		19.Apr.2005(19.04.2005)				
Name and mailing address of the IPEA/CN The State Intellectual Property Office, 6 Xitucheng Rd., Jimen Bridge, Haid Beijing, 100088, China	dian District,	Authorized officer	7			
Facsimile No. 86-10-62019451		Telephone No. 86-10-62	085232			

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/CN2004/000803

Box			of the report			
1.	Wi	th regard to	the language, this report is based on:			
	$\boxtimes$	the international application in the language in which it was filed				
		a transla	tion of the international application into,	which is the language of a		
		translation	1 furnished for the purposes of:	guuge of u		
			ational search (Rules 12.3(a) and 23.1(b))			
	publication of the international application (Rule 12.4(a))					
			ational preliminary examination (Rules 55.2(a) and/or 55.3(a))			
			(Ruics 55.2(a) and/or 55.5(a))			
2.	to t	th regard to he receiving nexed to this	the <b>elements</b> of the international application, this report is based on <i>(replaceme Office in response to an invitation under Article 14 are referred to in this reporeport)</i> :	nt sheets which have been furnished rt as "originally filed" and are not		
	$\boxtimes$		ational application as originally filed/furnished			
	$\boxtimes$	the descri	ption:			
		pages	1-12	as originally filed/furnished		
		pages *	received by this Authority on			
		pages *	received by this Authority on			
	$\boxtimes$	the claims:				
		pages	2	og originally filed/formisk - d		
		pages *		as originally filed/furnished with any statement)under Article 19		
		pages *	1 received by this Authority or	· · · · · · · · · · · · · · · · · · ·		
		pages *	received by this Authority of			
Г		the drawing pages pages pages a sequence	received by this Authority on received by this Authority on listing and/or any related table(s) - see Supplemental Box Relating to Sequence	_ as originally filed/furnished		
3. [	_ ਕ		ments have resulted in the cancellation of:	Listing.		
J. E	73					
			description, pages			
			claims, Nos. 2			
			drawings, sheets/figs			
			sequence listing (specify):			
		☐ any	table(s) related to sequence listing (specify):			
4. [	] :	the c	has been established as if (some of) the amendments annexed to this report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the States report and I have been considered to go beyond the disclosure as filed, as indicated in the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to go beyond the states report and I have been considered to	applemental Box (Rule 70.2(c)).		
			lrawings, sheets/figs			
			sequence listing (specify):			
			table(s) related to sequence listing (specify):			
*	If i	tem 4 applie	es, some or all of those sheets may be marked "superseded."			

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/CN2004/000803

Box	No. V Reasoned statement unde citations and explanation		with regard to novelty, inventive such statement	step or industrial applicability;
1.	Statement:			
	Novelty (N)	Claims	1-11	YES
		Claims		NO NO
	Inventive step (IS)	Claims	4-11	YES
		Claims	1-3	NO NO
	Industrial applicability (IA)	Claims	1-11	YES
		Claims		NO

- 2. Citations and explanations (Rule 70.7)
  - 1). The application claims a cream that contains interferon liposome.
  - 2). The closest document in the international search report is as follows:
    - D1: US5853755A(PHARMADERM LABORATORIES LTD.)
- D1 disclosed a dermal formulation containing interferon liposome such as cream(for example. see the column 7, lines 4-10), wherein the membrance material was composed of phospholipid and the like. The amounts of the active ingredient between claim 1 and D1 are different, but on the basis of D1, it is obvious for the skilled person in the art to obtain the claims 1-3 with the aid of knowledge in the art. Therefore, claims 1-3 meet the requirement of Art.33(2), but they lack the inventive step of Art.33(3.)
- 3).D1 gave the instruction that interferon could be formulated into liposome for dermal use and some embodiments, but it didn't give the same embodiments as claims 4-11 or the suggestion of them, and claims 4-11 therefore meet the requirement of novelty of Art.33(2) and that of inventive step of Art.33(3).
- 4). Claims 1-11 can be easily carried out in the pharmaceutical industry, thus they meet the requirement of in industrial applicability of Art.33(4).